Shots:
- TransThera Sciences has entered into a royalty-bearing patent assignment & research collaboration deal with Neurocrine Biosciences to develop preclinical NLRP3 inhibitors for multiple diseases
- As per the deal, Neurocrine will gain exclusive ex-Greater China rights to develop, manufacture & commercialize NLRP3 inhibitors from TransThera’s NLRP3 portfolio, while TransThera will retain Greater China rights (Mainland, HK, Taiwan, & Macao), with both collaborating to advance NLRP3 technology
- Under the deal, TransThera will receive an upfront payment & research, development & sale milestone payments, with total deal value reaching up to ~$881.5M
Ref: TransThera Sciences | Image: TransThera Sciences & Neurocrine Biosciences | Press Release
Related News:- 4D Molecular Therapeutics Collaborates with Otsuka Pharmaceutical to Develop and Commercialize 4D-150 in the APAC Region
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
